Adoptive Cell Therapy Against Triple-Negative Breast Cancer Using a Novel tMUC1 Antibody-Derived CAR
Technical Report,15 Sep 2018,14 Sep 2019
University of North Carolina at Charlotte Charolotte United States
Pagination or Media Count:
We have completed most of Tasks 1, 2, and 3 which are all part of aim 1. We have received approval for IACUC and IRB protocol. We have completed the human CAR T cell constructs for the 2nd and 3rd generation CARs and confirmed the sequences. We have successfully completed cytolysis assays for the 2nd generation CAR on human TNBC cell lines in an antigen-specific manner. These CAR T cells do not lyse normal epithelial or fibroblast cell lines. We have shown that the 3rd generation CARs are well expressed on human T cells. The cytolysis assays using the 3rd generation CAR are ongoing. We have also generated the murine CARs and have successfully expressed the 2nd generation of the murine CARs on murine T cells. We also have shown successful cytolysis of murine TNBC cell line in an antigen-specific manner. A summary of the data are presented in the report. We have started some of the in vivo experiments in specific aim 2 in vivo.
- Medicine and Medical Research